SEEKING to clarify issues around
compounding of drugs without a
prescription, the US Food and Drug
Administration has issued draft
guidance proposing new rules.
Stakeholders are being invited
to comment on the drafts within
90 days, with key issues at stake
including quantity supplied, to
whom and in what locations.
The US has two standards - one
(503A) for specific patients, and a
more stringent 503B level for non
patient-specific orders.
Under the draft guidance the FDA
says it believes all activities taking
place at a registered outsourcing
facility at a single geographic
location should be subject to
503B and the FDA’s current good
manufacturing practices, to ensure
drugs made under different
standards are not accidentally co-mingled.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Apr 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.